首页> 外文期刊>Клиничесκая лабораторная диагностиκа >EXPRESSION OF MOLECULAR MARKERS IN LOW-GRADE CHONDRQSARCOMAS AND CARTILAGINOUS TUMORS WITH UNCERTAIN DIFFERENTIATION
【24h】

EXPRESSION OF MOLECULAR MARKERS IN LOW-GRADE CHONDRQSARCOMAS AND CARTILAGINOUS TUMORS WITH UNCERTAIN DIFFERENTIATION

机译:分化不确定的低级软骨肉瘤和软骨钙化中分子标志物的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Among the wide array of human neoplasms, primary tumors of bone are relatively uncommon and sundry group of solid tumors traditionally categorized according to their presumed mesenchymal differentiation. A locally aggressive or malignant group of cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior require additional ancillary studies for prompt diagnosis and appropriate surgical treatment. They are histologically, behaviorally and genetically diverse, their pathogenesis is poorly understood. Moreover, treatment options are limited with surgical resection continuing to provide the only possibility of cure in many cases. However, there has been tremendous progress in the last decade in understanding the molecular pathogenesis of sarcoma, which may ultimately lead to more effective therapy and prognostication for these rare malignancies (I). Atypical cartilaginous tumor/grade I chondrosarcomas behave as locally aggressive lesions, and only metastasize in exceptional cases. Only a small percentage of the IDHl mutations can be identified using the specific IDH1R132H antibody. Histologic grade is the most important predictor of local recurrence and metastasis in chondrosarcoma , commonly patents die from locally recurrent tumor of pelvis or scull, that is difficult to manage surgically. Association between ratio of matrix metalloproteinaise-1 and tissue inhibitor of metalloproteinase-l, expression of metalloproteinase-1, -2and-9, Col-lV, Cox-2, Bcl-2, Box in context with histological and clinical data could play a significant role in determining prognosis in patients with borderline cartilaginous tumors. The mandatory application of multidisciplinary care in management of atypical cartilaginous tumor/grade I chondrosarcomas with integration of histologic, molecular, radiographic and clinical data is difficult to overestimate.
机译:在各种各样的人类肿瘤中,骨原发性肿瘤相对较少见,根据其假定的间充质分化,传统上将其归类为实体瘤的杂类。具有局部形态特征和临床行为的软骨基质产生性肿瘤的局部侵袭性或恶性组需要进行额外的辅助研究,以便迅速诊断和采取适当的手术治疗。它们在组织学,行为和遗传学上是多种多样的,对其发病机理了解甚少。此外,在许多情况下,继续进行外科手术切除是唯一治愈的可能性,治疗选择受到限制。然而,在过去十年中,在了解肉瘤的分子发病机理方面取得了巨大进展,这可能最终导致对这些罕见恶性肿瘤的更有效的治疗和预后(I)。非典型软骨肿瘤/ I级软骨肉瘤表现为局部侵袭性病变,仅在特殊情况下才转移。使用特异性IDH1R132H抗体只能鉴定出很小比例的IDH1突变。组织学分级是软骨肉瘤局部复发和转移的最重要预测指标,通常专利死于骨盆或双侧ull的局部复发性肿瘤,难以手术治疗。基质金属蛋白酶-1的比率与金属蛋白酶-1的组织抑制剂,金属蛋白酶-1,-2和9,Col-1V,Cox-2,Bcl-2,Box的表达在组织学和临床数据方面的关联可以发挥一定的作用。在确定边缘性软骨肿瘤患者的预后中起重要作用。在组织学,分子,影像学和临床数据整合方面,多学科护理在非典型软骨肿瘤/ I级软骨肉瘤的治疗中的强制性应用很难被高估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号